OVER DEZE AFLEVERING
In this episode of Communicable, Emily McDonald and Josh Davis host Henning Bundgaard and Sami El-Dalati for a discussion on early oral antibiotic switch for endocarditis, focusing on the POET trial, led by Bundgaard, and its clinical impact seven years after the results were first published in 2019 [1]. The episode also covers the ‘prose’ and cons of early oral switch therapy, as well as broader challenges of implementing new evidence in practice when it goes against long-standing dogma.
References
- Iversen K, et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis, NEJM 2018. DOI: 10.1056/NEJMoa1808312
Further reading:
- Pries-Heje MM, et al. Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial, NEJM 2022. DOI: 10.1056/NEJMc2114046
- El-Dalati S, et al. Partial Oral Versus Intravenous Antibiotic Therapy for Endocarditis With Management by a Multidisciplinary Team: A Retrospective Cohort Study, OFID 2025. DOI: 10.1093/ofid/ofaf625
- McDonald EM, et al. Guidelines for Diagnosis and Management of Infective Endocarditis in Adults: A WikiGuidelines Group Consensus Statement, JAMA Netw Open 2023. DOI: 10.1001/jamanetworkopen.2023.26366
- European Society of Cardiology (ESC). 2023 ESC Guidelines for the management of endocarditis, 2023.
Engels
Verenigde Staten
IN DEZE AFLEVERING
TRANSCRIPTIE 🔗
Communicable E62: POET
===
[00:00:00]
Emily: Hello, everyone, and welcome back to Communicable, the podcast brought to you by CMI Communications, ESCMID's open access journal covering infectious diseases and clinical microbiology. I am Emily McDonald. I'm a physician in general internal medicine, infectious disease trialist and scientist at McGill University in Montreal, Canada, and associate editor at CMI Communications.
So, the POET trial, partial oral intravenous, antibiotic treatment of …
===
[00:00:00]
Emily: Hello, everyone, and welcome back to Communicable, the podcast brought to you by CMI Communications, ESCMID's open access journal covering infectious diseases and clinical microbiology. I am Emily McDonald. I'm a physician in general internal medicine, infectious disease trialist and scientist at McGill University in Montreal, Canada, and associate editor at CMI Communications.
So, the POET trial, partial oral intravenous, antibiotic treatment of …
OUDE AFLEVERINGEN ZOEKEN
Zoek naar eerdere afleveringen van Communicable.
Disclaimer: De podcast en de illustraties die op deze pagina zijn ingesloten, zijn afkomstig van CMI Communications, eigendom van de eigenaar en niet gelieerd aan of goedgekeurd door Listen Notes, Inc.
BEWERKEN
Bedankt voor uw hulp bij het up-to-date te houden van de podcast-database .